Quality Of Life Was Not Negatively Impacted By The Addition Of Lenalidomide To R-Chop Chemotherapy (R-2-Chop) Compared With Placebo Plus R-Chop Chemotherapy In Patients With Previously Untreated Activated B-Cell (Abc)-Type Diffuse Large B-Cell Lymphoma (Dlbcl): Health-Related Quality Of Life (Hrqol) Analysis Of The International Robust Study

Introduction: The phase 3 international, randomized, double-blind ROBUST clinical trial (NCT02285062) compared progression-free survival between patients with previously untreated ABC-type DLBCL treated with placebo plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (placebo-R-CHOP) versus lenalidomide + R-CHOP (R2-CHOP) for 6 21-day cycles. HRQoL, as measured by the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and the EuroQoL 5-dimension 3-level (EQ-5D-3L) patient-reported questionnaires, was evaluated as a secondary endpoint for the 2 treatment arms.